Abstract
Three novel 8-oxo-dGTP bisphosphonate analogues of 3 in which the bridging β,γ-oxygen is replaced by a methylene, fluoromethylene or difluoromethylene group (4–6, respectively) have been synthesized from 8-oxo-dGMP 2 by reaction of its morpholine 5’-phosphoramidate 14 or preferably, its N-methylimidazole 5’-phosphoramidate 15 with n-tributylammonium salts of the appropriate bisphosphonic acids, 11–13. The latter method also provides a convenient new route to 3. Analogues 4–6 may be useful as mechanistic probes for the role of 3 in abnormal DNA replication and repair.
Keywords: 8-Oxo-dGTP; β,γ-Methylene 8-oxo-dGTP; β,γ-Monofluoromethylene 8-oxo-dGTP; β,γ-Difluoromethylene 8-oxo-dGTP; DNA polymerases
Graphical Abstract

Introduction
Oxidative DNA damage due to reactive oxygen species (ROS) has been implicated in the pathogenesis of a wide variety of diseases, including cancer,1 neurodegenerative and neurodevelopmental disorders,2 inflammatory disorders3 and aging.4 8-Oxo-2’-deoxyguanosine (8-oxo-dG, 1) is a harbinger of oxidative DNA damage5 and has been implicated in carcinogenesis by inducing mutations6 as well as by abnormal epigenetic modulation of gene expression.7 The mutagenicity of 1 is attributed to a conformational shift of the N9-C1’ glycosidic bond from anti to syn, causing it to mimic a syn thymidine.8 As a result of A:8-oxo-G (A:8OG) Hoogsteen base mispairing, replicative DNA polymerases (pols) often insert dATP opposite 1 instead of dCTP.9,10 Pol β, pol η, REV1, pol ξ and pol κ have all been implicated11 in the incorporation of 8-oxo-dGMP 2 into DNA from 8-oxo-2’-deoxyguanosine-5’-triphosphate (8-oxo-dGTP, 3), present as an ROS in the cellular nucleotide pool.12 Wilson and co-workers recently described the crystal structure of a pol β DNA complex in which the adenine of a DNA (syn)8OG:A base pair was replaced at the primer terminus by a cytosine.13 It is apparent that complementary information about the functional mechanism and transition state (TS) is desirable.
Herein, we report the synthesis of a small toolkit of 8-oxo-dGTP bisphosphonate probes, including an alternate preparation of the reference nucleotide, 3. The toolkit comprises three β,γ-CXY bridged 8-oxo-dGTP analogues: β,γ-methylene- 4, β,γ-monofluoromethylene- 5, and β,γ-difluoromethylene-8-oxo-dGTP 6 (Fig. 1).
Figure 1.

Structures of 8-oxo-dGTP 3, β,γ-CH2- 4, β,γ-CHF- 5, and β,γ-CF2-8-oxo-dGTP 6.
A similar toolkit based on the natural nucleotides has been used to study leaving group effects on the nucleotidyl transfer kinetic mechanisms and fidelity of pols14–18 and other biocatalysts.19 As the β,γ-bridge atom X and Y substituents become more electronegative, the pKa4 of the corresponding bisphosphonate leaving group decreases,20, 21 stabilizing the conjugate base anion. If the rate-determining step (RDS) involves P-O bond breaking, then a Bronsted plot of the log of the catalytic rate constant (kpol) versus pKa4 is predicted to be linear (linear free energy relationship, LFER) with a negative slope reflecting the sensitivity of the TS to anion stabilization.22 The bisphosphonates selected provide a range of pKa4 of 2.75 units, centered on the pKa4 of the leaving group in 3, pyrophosphoric acid.20
Results and Discussion
Early oxidative methods12, 23 to prepare 3 itself directly from dGTP in low or unstated yield were not reproduced by others,24 as confirmed by own work (data not shown). Direct oxidative methods have a further limitation in that they do not give convenient access to 8-[17O]- or 8-[18O]-oxo-guanosine derivatives.25 Einolf described an 8-step synthesis of 3 beginning from dG 7 involving several protection/deprotection steps, culminating in separation of the final compound from mono- and diphosphate 8-oxo-dG byproducts.26 Nampalli and Kumar24 subsequently outlined a gram-scale synthesis of 3 from 8-bromo-dG27, 28 8 in 36% overall yield via conversion to the 8-benzyloxy derivative 9 using sodium/benzyl alcohol in dimethyl sulfoxide, followed by treatment with phosphorus oxychloride (POCl3)29 in trimethyl phosphate and reaction with bis(tributylammonium) pyrophosphate. The final product was obtained by hydrolysis of the resulting cyclic triphosphate intermediate in aqueous triethylammonium bicarbonate (TEAB) at pH 7.5 (Scheme 1 and 2).24
Scheme 1.

Scheme 2.

‘One-pot’ phosphorylation30, 31 synthesis of 8-oxo-dGTP 3 from 8-oxo-dG 1;24 (TEAB: triethylammonium bicarbonate buffer)
8-Benzyloxy-dG 9 can be prepared from 7 in 78% yield,27, 28 and we found that formation of an 8-dimsyl-dG byproduct can be avoided by using DMF in place of DMSO as the solvent (Scheme 1). However, in our hands, phosphorylation of 1 or 9 on a small scale using the literature one-pot-three-step procedure24, 30, 31 (Scheme 2) gave lower yields than anticipated.
We therefore examined an alternative synthesis of 3 starting from 8-oxo-dGMP 2 (prepared in 33% yield by monophosphorylation of 1 with POCl3 in PO(OMe)329 followed by aqueous workup with 0.5 M TEAB) after activation by morpholine32 or N-methylimidazole33, 34 to facilitate coupling with pyrophosphate 10, as a method likely to be adaptable to the synthesis of 4–6 from the appropriate bisphosphonate tributylammonium salt 11–13,20 prepared by treatment of commercially available methylenebis(phosphonic acid) or its α-fluorinated derivatives35 with tributylamine in aq. ethanol. 8-Oxo-dGMP-morpholidate 14 gave 3 and the target bisphosphonate nucleotides 4–6, but the reactions were sluggish, with very poor yields (Scheme 3).
Scheme 3.

Synthesis of 3–6 via the 5’-morpholidate 14.
Better results were obtained with N-methylimidazole activation.33, 34 Thus, 2 suspended in a mixture of triethylamine and excess trifluoroacetic anhydride in acetonitrile was treated with N-methylimidazole to give the corresponding 8-oxo-dGMP-N-methylimidazolide 15, which was then added to tributylammonium pyrophosphate 10 or the tributylammonium bisphosphonate 11, 12 or 13 in DMF (Scheme 4). Deactivated 8-oxo-dGMP 2 can be recovered during purification of the final products (characterized by 1H, 31P and 19F NMR, LC-MS and HRMS) via SAX/C-18 preparative HPLC.
Scheme 4.

Synthesis of 3–6 via the 5’-N-methylimidazolide 15.
In the coupling reactions to form 3–6, the reaction time was much shorter with the N-methylimidazolides (2–3 h) compared to the morpholidates (3–5 d).30–32 It is critical to thoroughly dry the tributylammonium salt of the bisphosphonic acid by repeated coevaporation with anhydrous N,N-dimethylformamide before use to achieve optimal yields.
The proton-decoupled 31P NMR spectra of 3–6 are compared in Figure S44. As expected, a dramatic upfield shift of the Pγ and Pβ resonances is seen with more electronegative substituents (CF2 > CHF > CH2) on the bridging β-methylene group. There is no effect on the Pα resonance which remains constant at about −10 ppm.
Consistent with published data for the β,γ-monofluoro and β,γ-difluoro analogues of dGTP,15 5 and 6 exhibit 19F NMR resonances at δ −217.3 and δ −121. ppm, respectively. The 31Pβ, 31Pγ and 19F peaks of 5 exhibit a slight broadening consistent with a small Δδ for the R v S diastereomers.15
Conclusion
In summary, we examined several alternative approaches for the synthesis of 8-oxo-dGTP 3 and three novel bisphosphonate analogues: β,γ-methylene- 4, (R/S)-β,γ-monofhioromethylene- 5, and β,γ-difluoromethylene-8-oxo-dGTP 6. Conjugation of the corresponding bisphosphonic acid tributylammonium salts 11–13 with 8-oxo-dGMP-N-methylimidazolide 15 in anhydrous DMF is a practical route to these compounds, albeit in low (not optimized) yields. The availability of the resulting 8-oxo-dGTP analogue toolkit provides a novel means to probe leaving group effects on the binding and kinetic mechanisms of 3 interacting with nucleic acid polymerases.
Supplementary Material
Highlights:
8-Oxo-dGTP plays a key role in oxidative DNA mutation pathways.
8-Oxo-GTP and 3 novel β,γ-CXY analogues were synthesized via 5’-P-imidazolides.
This leaving group-modified toolkit provides useful probes for DNA polymerases.
Acknowledgments
We thank Prof. N. A. Graham and A. Delfarah for assistance in obtaining the high-resolution mass spectra. NIH grant U19CA177547 partially supported this work. Pouya Haratipour was a USC Dornsife Chemical Biology Trainee.
Footnotes
Declaration of interests
☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Electronic Supporting Information
Electronic Supporting Information associated with this article, including details of synthetic procedures with spectroscopic and other characterization data, can be found in the online version.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
- 1.Scott TL; Rangaswamy S; Wicker CA; Izumi T Antioxid Redox Signal 2014, 20, 708. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Andersen JK Aat. Med. 2004, 10, 18. [Google Scholar]
- 3.Ba X; Aguilera-Aguirre L; Sur S; Boldogh I Curr Opin Allergy Clin Immunol 2015, 15, 89. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Hamilton ML; Van Remmen H; Drake JA; Yang H; Guo ZM; Kewitt K; Walter CA; Richardson A Proc. Aatl. Acad. Sci. U. S. A. 2001, 98, 10469. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Shigenaga MK; Aboujaoude EN; Chen Q; Ames BN Meth Enzymol, 1994, 234. pp 16. [DOI] [PubMed] [Google Scholar]
- 6.Suzuki T; Kamiya H Genes Environ. 2017, 39, 2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Mahalingaiah PK; Ponnusamy L; Singh KP Oncotarget 2017, 8, 11127. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Burak MJ; Guja KE; Hambardjieva E; Derkunt B; Garcia-Diaz M EMBO J. 2016, 35, 2045. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Shibutani S; Takeshita M; Grollman AP Aature 1991, 349, 431. [DOI] [PubMed] [Google Scholar]
- 10.Krahn JM; Beard WA; Miller H; Grollman AP; Wilson SH Structure 2003, 11, 121. [DOI] [PubMed] [Google Scholar]
- 11.van Loon B; Woodgate R; Hubscher U DNA Repair 2015, 29, 1. [DOI] [PubMed] [Google Scholar]
- 12.Mo JY; Maki H; Sekiguchi M Proc. Aatl. Acad. Sci. U. S. A. 1992, 89, 11021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Batra VK; Wilson SH Commun. Biol. 2020, 3, 348. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Sucato CA; Upton TG; Kashemirov BA; Osuna J; Oertell K; Beard WA; Wilson SH; Florian J; Warshel A; McKenna CE; Goodman MF Biochemistry 2008, 47, 870. [DOI] [PubMed] [Google Scholar]
- 15.Wu Y; Zakharova VM; Kashemirov BA; Goodman MF; Batra VK; Wilson SH; McKenna CE J. Am. Chem. Soc. 2012, 134, 8734. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Oertell K; Kashemirov BA; Negahbani A; Minard C; Haratipour P; Alnajjar KS; Sweasy JB; Batra VK; Beard WA; Wilson SH; McKenna CE; Goodman MF Biochemistry 2018, 57, 3925. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Batra VK; Oertell K; Beard WA; Kashemirov BA; McKenna CE; Goodman MF; Wilson SH Biochemistry 2018, 57, 3934. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Alnajjar KS; Krylov IS; Negahbani A; Haratipour P; Kashemirov BA; Huang J; Mahmoud M; McKenna CE; Goodman MF; Sweasy JB Aucleic Acids Res. 2019, 47, 11839. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Setterholm NA; Haratipour P; Kashemirov BA; McKenna CE; Joyce GF Biochemistry 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Haratipour P; Minard C; Nakhjiri M; Negahbani A; Chamberlain BT; Osuna J; Upton TG; Zhao M; Kashemirov BA; McKenna CE J. Org. Chem. 2020, 85, 14592. [DOI] [PubMed] [Google Scholar]
- 21.McKenna CE; Haratipour P; Duro MVV; Ebetino FH Chemistry of Bisphosphonates. In Enclopedia of Bone Biology; Saidi M Ed.; Elsevier, 2020. pp 551. [Google Scholar]
- 22.Mihai C; Kravchuk AV; Tsai MD; Bruzik KS J. Am. Chem. Soc. 2003, 125, 3236. [DOI] [PubMed] [Google Scholar]
- 23.Kasai H; Nishimura S Aucleic Acids Res. 1984, 12, 2137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Nampalli S; Kumar S Bioorg. Med. Chem. Lett. 2000, 10, 1677. [DOI] [PubMed] [Google Scholar]
- 25.Hermanns RCA; Zomer G; Jacquemijns M; Stavenuiter JFC; Westra JG; Teixeira AJR; Van De Werken GJ Labelled Compd. Radiopharm. 1994, 34, 191. [Google Scholar]
- 26.Einolf HJ; Schnetz-Boutaud N; Guengerich FP Biochemistry 1998, 37, 13300. [DOI] [PubMed] [Google Scholar]
- 27.Lin TS; Cheng JC; Ishiguro K; Sartorelli AC J. Med. Chem. 1985, 28, 1194. [DOI] [PubMed] [Google Scholar]
- 28.Gannett PM; Sura TP Synth. Commun. 1993, 23, 1611. [Google Scholar]
- 29.Yoshikawa M; Kato T; Takenishi T Tetrahedron Lett. 1967, 506. [DOI] [PubMed] [Google Scholar]
- 30.Ludwig J Acta Biochim. Biophys. Acad. Sci. Hung. 1981, 16, 131. [PubMed] [Google Scholar]
- 31.Ruth JL; Cheng YC Mol. Pharmacol 1981, 20, 415. [PubMed] [Google Scholar]
- 32.Moffatt JG; Khorana HG J. Am. Chem. Soc. 1961, §3, 649. [Google Scholar]
- 33.Bogachev VS Bioorg Khim 1996, 22, 699. [Google Scholar]
- 34.Mohamady S; Jakeman DL J. Org. Chem. 2005, 70, 10588. [DOI] [PubMed] [Google Scholar]
- 35.McKenna CE; Shen PD J. Org. Chem. 1981, 46, 4573. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
